Profile data is unavailable for this security.
About the company
Aelis Farma SA is a France-based company that is specialized in the research and development of drugs for the treatment of disorders of Central Nervous System (CNS). The Company provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). It offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. It provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The Company operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.
- Revenue in EUR (TTM)446.00k
- Net income in EUR-8.20m
- Incorporated2013
- Employees26.00
- LocationAelis Farma SA1 Rue Lafaurie de MonbadonBORDEAUX 33000FranceFRA
- Phone+33 557573770
- Websitehttps://www.aelisfarma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Perseus Proteomics Inc | 664.06k | -4.30m | 19.12m | 32.00 | -- | 3.33 | -- | 28.79 | -53.50 | -53.50 | 8.27 | 71.39 | 0.0668 | 1.85 | 10.22 | 3,810,875.00 | -43.18 | -38.61 | -46.14 | -40.75 | 87.27 | 90.16 | -646.80 | -837.30 | 14.76 | -- | 0.00 | -- | 19.89 | 7.02 | 18.08 | -- | 95.88 | -- |
| PuraPharm Corp Ltd | 37.29m | -4.15m | 19.30m | 469.00 | -- | 1.30 | 12.31 | 0.5177 | -0.0976 | -0.0976 | 0.8778 | 0.2568 | 0.4749 | 1.39 | 6.98 | 723,920.70 | -5.28 | -6.50 | -15.35 | -14.97 | 53.93 | 59.22 | -11.12 | -14.08 | 0.3313 | -1.14 | 0.7865 | -- | -6.09 | -11.30 | 66.59 | -- | -29.92 | -- |
| Indofarma Tbk PT | 10.32m | -14.77m | 19.66m | 21.00 | -- | -- | -- | 1.90 | -95.22 | -95.22 | 66.55 | -287.47 | 0.3078 | 4.86 | 3.42 | 261,731,600.00 | -44.04 | -22.37 | -- | -86.55 | -18.08 | 10.25 | -143.08 | -24.49 | 0.1006 | -67.63 | -- | -- | -59.82 | -31.14 | 53.61 | -- | -30.35 | -- |
| Aelis Farma SA | 446.00k | -8.20m | 19.87m | 26.00 | -- | 3.25 | -- | 44.56 | -0.5998 | -0.5998 | 0.0326 | 0.4461 | 0.0247 | -- | 0.5826 | 17,153.85 | -45.48 | -24.79 | -64.80 | -40.70 | -- | -- | -1,837.89 | -115.10 | -- | -- | 0.4907 | -- | -70.42 | -- | -46.83 | -- | 39.47 | -- |
| Brooks Laboratories Ltd | 8.25m | 2.00m | 20.28m | 323.00 | 10.14 | -- | 9.43 | 2.46 | 7.32 | 7.32 | 30.45 | -- | -- | -- | -- | 2,750,638.00 | -- | -14.21 | -- | -23.39 | 38.75 | 25.99 | 24.31 | -25.22 | -- | -- | -- | -- | 3.86 | 3.45 | 49.13 | -- | -18.61 | -- |
| Dare Bioscience Inc | 23.28k | -14.68m | 20.30m | 21.00 | -- | 8.24 | -- | 872.11 | -1.92 | -1.92 | 0.0029 | 0.2052 | 0.0011 | -- | 0.0624 | 1,318.57 | -71.56 | -91.64 | -241.96 | -243.93 | 127.70 | -- | -63,069.55 | -1,024.05 | -- | -156.39 | 0.7177 | -- | -99.65 | -- | 86.56 | -- | -- | -- |
| Avecho Biotechnology Ltd | 821.26k | -2.16m | 20.76m | 29.00 | -- | 36.54 | -- | 25.28 | -0.0011 | -0.0011 | 0.0004 | 0.0003 | 0.2115 | 4.46 | 1.91 | -- | -55.49 | -61.23 | -72.92 | -73.27 | 62.27 | 55.45 | -262.41 | -382.04 | 4.53 | -8.03 | 0.0647 | -- | 139.19 | -23.20 | 9.15 | -- | -- | -- |
| Aytu Biopharma Inc | 52.66m | -20.65m | 20.84m | 82.00 | -- | 1.75 | -- | 0.3958 | -3.40 | -3.39 | 5.63 | 1.32 | 0.5259 | 2.10 | 2.22 | 763,902.40 | -20.62 | -26.47 | -45.22 | -47.32 | 66.84 | 60.56 | -39.21 | -52.54 | 1.03 | 0.057 | 0.5958 | -- | 1.84 | 19.16 | -13.27 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Groupama Asset Management SAas of 31 Jan 2025 | 24.81k | 0.18% |
